Latest News

Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.

NasdaqGS:BIIB
NasdaqGS:BIIBBiotechs

Biogen (BIIB) Valuation Check After FDA Breakthrough Therapy Designation For Litifilimab

Biogen (BIIB) is back in focus after the U.S. Food and Drug Administration granted Breakthrough Therapy Designation to its investigational drug litifilimab for cutaneous lupus erythematosus, highlighting renewed regulatory attention on its pipeline. See our latest analysis for Biogen. Biogen’s latest FDA updates come after a 19.93% 90 day share price return and a 25.82% 1 year total shareholder return. However, 3 and 5 year total shareholder returns remain sharply negative, suggesting recent...
NasdaqGS:TXN
NasdaqGS:TXNSemiconductor

Assessing Texas Instruments (TXN) Valuation After Strong Guidance And Data Center Growth Signals

Texas Instruments (TXN) is back in focus after issuing first quarter 2026 guidance that topped analyst expectations, with management highlighting sharp year over year growth in its data center business as a key driver. See our latest analysis for Texas Instruments. The upbeat guidance and data center commentary arrived after a sharp swing in sentiment, with the share price climbing to US$225.01 on the back of a 26.8% year to date share price return and a 41.2% 90 day share price return, while...
NasdaqGS:NBIX
NasdaqGS:NBIXBiotechs

How Investors Are Reacting To Neurocrine Biosciences (NBIX) Launching Phase 2 Trial For Longer-Acting TD Drug

In late January 2026, Neurocrine Biosciences began a Phase 2 randomized, double-blind, placebo-controlled trial of its investigational VMAT2 inhibitor NBI-1065890 in about 100 adults with tardive dyskinesia, measuring changes in Abnormal Involuntary Movement Scale scores over eight weeks. This move extends Neurocrine’s two decades of VMAT2 research and existing FDA-approved valbenazine franchise, aiming to explore potentially longer-acting treatment options for movement disorders. We’ll now...
NYSE:IONQ
NYSE:IONQTech

IonQ’s Vertical Quantum Stack Reshapes Growth Prospects And Investor Tradeoffs

IonQ has moved to become a fully vertically integrated quantum computing company through recent acquisitions. The company has completed its purchase of Skyloom Global and plans to acquire SkyWater Technology. These deals add in house chip manufacturing and secure quantum networking capabilities to IonQ's platform. IonQ, listed as NYSE:IONQ, now combines quantum hardware, chip production, and networking under one roof, aiming to create a tightly controlled technology stack. The shares most...
NYSE:FICO
NYSE:FICOSoftware

Does Fair Isaac's (FICO) New AI Partnership Redefine Its Long-Term Competitive Moat?

In late January 2026, Fair Isaac reported first-quarter fiscal 2026 results with revenue of US$511.96 million and net income of US$158.37 million, reaffirmed its full-year outlook, and announced a global partnership with Tech Mahindra to expand AI-powered decisioning for financial institutions via a new FICO Platform Centre of Excellence. Together with enhancements to its FICO Score 10T mortgage tools, continued share repurchases, and recognition in Gartner’s 2026 Critical Capabilities...
NYSE:MAN
NYSE:MANProfessional Services

Is ManpowerGroup (MAN) Now Trading At An Attractive Price After Recent Share Rebound?

If you are looking at ManpowerGroup and wondering whether the recent share price puts it in bargain or trap territory, you are in the right place to focus on what the current valuation is really telling you. The stock recently closed at US$36.68, with a 20.7% return over the past week and 22.0% over the past month, although the 1 year return sits at a 34.5% decline and the 3 and 5 year returns are 53.6% and 52.9% declines respectively. Recent attention on ManpowerGroup has centered around...
NasdaqGS:ASTS
NasdaqGS:ASTSTelecom

SHIELD Defense Win And BlueBird 7 Launch Might Change The Case For Investing In AST SpaceMobile (ASTS)

In January 2026, AST SpaceMobile secured a prime contract position on the U.S. Missile Defense Agency’s SHIELD program and announced a late-February New Glenn launch from Cape Canaveral for its next-generation BlueBird 7 satellite, which carries a nearly 2,400-square-foot phased-array for space-based cellular broadband. Together, the SHIELD award and BlueBird 7 mission highlight how AST SpaceMobile’s commercial 4G/5G platform is being adapted for dual-use defense roles such as command,...
NYSE:DVN
NYSE:DVNOil and Gas

Is Devon Energy (DVN) Pricing Reflect Its Mixed Multi Year Share Performance?

If you are wondering whether Devon Energy at around US$40.14 is giving you enough value for the risk you are taking, you are asking the right question. The share price moves over the last year have been mixed, with returns of 3.9% over 7 days, 6.0% over 30 days, 6.0% year to date, 22.2% over 1 year, a 24.6% decline over 3 years, and 177.4% over 5 years. Recent attention on Devon Energy has been driven more by its role in the US oil and gas sector and shifting sentiment toward energy stocks,...
NasdaqGS:FANG
NasdaqGS:FANGOil and Gas

Is It Time To Reconsider Diamondback Energy (FANG) After Recent Valuation Signals

If you are wondering whether Diamondback Energy is priced attractively right now, you are not alone. Many investors are asking if the current share price reflects its underlying value. The stock recently closed at US$158.64, with returns of 3.3% over 7 days, 4.1% over 30 days and year to date, and a 0.8% decline over the last year. The 3 year and 5 year returns sit at 31.2% and 184.3% respectively. Recent market interest has been shaped by company updates and sector headlines that investors...
NYSE:CPNG
NYSE:CPNGMultiline Retail

Is Coupang (CPNG) Pricing Look Attractive After Recent Share Price Decline?

If you are wondering whether Coupang's current share price still reflects its long term potential, this article walks through what the numbers are saying about value today. Coupang's stock most recently closed at US$20.04, with returns of 2.4% over the last 7 days, a 14.2% decline over the last 30 days, a 14.2% decline year to date, and a 15.0% decline over the last year, while the 3 year return sits at 21.4%. Recent attention around Coupang has centered on its position in the South Korean e...
XTRA:MUV2
XTRA:MUV2Insurance

Assessing Munich Re (XTRA:MUV2) Valuation After India’s Insurance FDI Liberalization

Recent rule changes in India increasing the foreign direct investment limit in insurance to 100% and opening GIFT City to more global reinsurers have put Münchener Rückversicherungs-Gesellschaft in München (XTRA:MUV2) in sharper focus for investors. See our latest analysis for Münchener Rückversicherungs-Gesellschaft in München. The FDI rule change in India comes as Münchener Rückversicherungs-Gesellschaft in München’s share price has eased recently, with a 30 day share price return of 4.22%...
NasdaqGS:ASML
NasdaqGS:ASMLSemiconductor

Assessing ASML Holding (NasdaqGS:ASML) Valuation After Its Strong Recent Share Price Momentum

Why ASML Holding (NasdaqGS:ASML) is Back on Many Watchlists ASML Holding (NasdaqGS:ASML) has been getting fresh attention after a strong run in its share price over the past month and past 3 months, prompting investors to reassess what they are paying for its earnings power. See our latest analysis for ASML Holding. The recent move to a US$1,441.39 share price sits alongside a 30 day share price return of 23.85% and a 1 year total shareholder return of 98.77%. This points to strong momentum...
NYSE:HRL
NYSE:HRLFood

A Look At Hormel Foods (HRL) Valuation As Softer Demand Pressures Margins And Earnings

Soft demand, tighter margins put Hormel Foods (HRL) profitability in focus Hormel Foods (HRL) is under pressure as declining unit sales over the past two years, weaker gross margins than peers, and falling earnings per share against roughly flat revenue raise fresh questions about its profit profile. See our latest analysis for Hormel Foods. At a share price of $24.46, Hormel Foods has had a 90 day share price return of 13.35% and a 1 month share price return of 4.57%. Its 1 year total...
NasdaqGS:ENTG
NasdaqGS:ENTGSemiconductor

Assessing Whether Entegris (ENTG) Shares Look Overvalued After Recent Momentum

Why Entegris is on investors’ radar today Entegris (ENTG) has attracted fresh attention after a strong month, with the share price recently closing at $119.48. That move, paired with its recent return profile, is prompting closer scrutiny from investors. See our latest analysis for Entegris. The recent 33.4% 1 month share price return, alongside a 38.2% 3 month share price return and 20.6% 1 year total shareholder return, points to momentum building around Entegris after a softer period...